EUVIMEDEUVIMED entdecken
Crossref

Normal organ [68Ga]DOTATOC uptake during PRRT: challenging the assumption of stable background shaped by cold somatostatin analogues treatment

Hind Ait Talhiq, Philippe Baltzinger, Juliette Frega, Cedric Collen, Maximilien Colin Valentin, Gabriel G Malouf, Clemence Porot, Meher Ben Abdelghani, Pietro Addeo, Bernard Goichot, Valentina Berti, Alessio Imperiale iD

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-025-07648-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Hind Ait Talhiq und 11 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe (ICANS), University Hospitals of Strasbourg, University of Strasbo…. Hauptthemen laut MEDLINE: Octreotide, Organometallic Compounds, Neuroendocrine Tumors, Somatostatin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To characterize longitudinal changes in normal-organ [68Ga]DOTATOC uptake through sequential PET/CT during [177Lu]DOTATATE PRRT in patients with small intestine neuroendocrine tumors (SiNET) and to relate these changes to the somatostatin-analogue (SSA) regimen, early PET response after two PRRT cycles, and 1-year outcome. METHODS: Thirty-four patients who underwent [68Ga]DOTATOC PET/CT before PRRT (PET-baseline), after two cycles (PET-interim), and at treatment completion (PET-end) were retrospectively included. At study entry, all patients received long-acting SSA, which was discontinued during PRRT. The mean SSA-to-scan intervals were 22.1 ± 9.4 days (baseline), 125.9 ± 19.7 days (interim), and 326.2 ± 26.9 days (end). SUVmax was measured in 11 organs. Wilcoxon test with Bonferroni correction was used for group comparisons, Pearson for correlations, and two-sided Mann-Whitney U test for subgroup analyses. RESULTS: The most significant, consistent changes occurred in the liver and spleen, both of which significantly increased from PET-baseline to PET-interim and further to PET-end (liver: +61%, spleen: +103%, p < 0.01) and evolved in parallel (r = 0.64-0.71). Hepatic uptake continued to rise through the end of PRRT and remained elevated long after the last SSA injection. At interim, liver SUVmax was higher in early PET responders than in non-responders and in patients who later progressed at one year; the spleen showed a similar pattern. These findings suggest an SSA-timing-sensitive background drift superimposed on treatment effects. CONCLUSION: Normal organ [68Ga]DOTATOC uptake during PRRT is dynamic and influenced by SSA regimen and scan timing. Liver and spleen are unreliable as stable references, underscoring the need for harmonized PET timing and explicit reporting of SSA-to-scan intervals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OctreotideOrganometallic CompoundsNeuroendocrine TumorsSomatostatinIntestinal NeoplasmsHumansMaleFemaleMiddle AgedPositron Emission Tomography Computed TomographyAgedAdultRetrospective StudiesBiological TransportRadiopharmaceuticals

Stichwörter der Autor:innen

NeuroendocrineNormal organPeptide receptor radionuclide therapy[177Lu]DOTATATE[68Ga]DOTATOC

Substanzen

OctreotideOrganometallic CompoundsSomatostatinGa(III)-DOTATOCRadiopharmaceuticals

Autor:innen und Institutionen

  • Nuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe (ICANS), University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, France.
  • Nuclear Medicine, Faculté de Médecine et de Pharmacie, Centre Hospitalo-Universitaire Mohammed VI, Marrakech, Morocco.
  • Endocrinology, Diabetology, Nutrition, University Hospitals of Strasbourg, Strasbourg University, Strasbourg, France.
  • Institut de Cancérologie Strasbourg Europe (ICANS), University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, France.
  • Institut de Cancérologie Strasbourg Europe (ICANS), Radiopharmacy, Strasbourg, France.
  • Institut de Cancérologie Strasbourg Europe (ICANS), Gastroenterology, Strasbourg, France.

ORCID-Profile: Alessio Imperiale

Zitieren

APA

Ait Talhiq, H., Baltzinger, P., Frega, J., Collen, C., Colin Valentin, M., Malouf, G. G., Porot, C., Abdelghani, M. B., Addeo, P., Goichot, B., Berti, V., & Imperiale, A. (2026). Normal organ [68Ga]DOTATOC uptake during PRRT: challenging the assumption of stable background shaped by cold somatostatin analogues treatment. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07648-7

Vancouver

Ait Talhiq H, Baltzinger P, Frega J, Collen C, Colin Valentin M, Malouf GG, et al. Normal organ [68Ga]DOTATOC uptake during PRRT: challenging the assumption of stable background shaped by cold somatostatin analogues treatment. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07648-7

BibTeX
@article{AitTalhiq2026,
  author = {Ait Talhiq, Hind and Baltzinger, Philippe and Frega, Juliette and Collen, Cedric and Colin Valentin, Maximilien and Malouf, Gabriel G and Porot, Clemence and Abdelghani, Meher Ben and Addeo, Pietro and Goichot, Bernard and Berti, Valentina and Imperiale, Alessio},
  title = {Normal organ [68Ga]DOTATOC uptake during PRRT: challenging the assumption of stable background shaped by cold somatostatin analogues treatment},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-025-07648-7}
}
Kostenlos starten →